Silence Therapeutics plc (SLN) Market Cap & Valuation Ratios
Silence Therapeutics plc (SLN) has a market cap of $929.3M and a price-to-sales ratio of 1511.1, with earnings according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
SLNSilence Therapeutics plcFollow SLN — free
—
Price chart with a free account
- Market cap
- 929.3M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 5 Nov, in 12 days
Peers
drug manufacturers - general · nearest by market cap · trailing 12 months| Company | Mkt cap, $B | P/E | EV/Sales | EV/EBITDA | FCF yield | Rev. growth | Op. margin | ROIC |
|---|---|---|---|---|---|---|---|---|
| SLN | 0.9 | — | — | — | -4.5% | -98% | — | — |
| GENB | 1.6 | — | — | — | — | — | — | — |
| QURE | 1.6 | — | 42.6 | — | -10.4% | +30% | — | — |
| CMPS | 1.5 | — | — | — | — | — | — | — |
| GPCR | 1.5 | — | — | — | -14.9% | — | — | -30% |
| MLTX | 1.0 | — | — | — | — | — | — | -315% |
| NVCT | 0.7 | — | — | — | — | — | — | — |
| GYRE | 0.7 | — | 5.0 | — | -0.9% | +17% | -14% | -28% |
| AKTX | 0.6 | — | — | — | -1.6% | — | — | -175% |
| PBYI | 0.6 | 21.2 | 2.1 | 11.6 | 7.2% | -3% | 13% | 27% |
| STTK | 0.6 | — | 487.7 | — | -7.5% | -67% | — | -72% |
| Median of these 10 | 21.2 | 23.8 | 11.6 | -4.6% | +7% | -0.4% | -51% |
.
Growth vs. price
each dot a company · hover or tap for valuesSilence Therapeutics plc — questions
- What is Silence Therapeutics plc's market cap?
- $929.3M.
- What is Silence Therapeutics plc's price-to-sales ratio?
- 1511.1.
Every figure on this page comes from Silence Therapeutics plc's own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.